Characterisation and manipulation of docetaxel resistant prostate cancer cell lines

[1]  Robert Clarke,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy , 2012 .

[2]  R. Sutherland,et al.  Pathways of chemotherapy resistance in castration-resistant prostate cancer. , 2011, Endocrine-related cancer.

[3]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[4]  Малколм Филип Янг,et al.  Cancer cell apoptosis , 2010 .

[5]  L. O’Driscoll,et al.  Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines , 2010, Investigational New Drugs.

[6]  J. O’Sullivan,et al.  Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro , 2009, British Journal of Cancer.

[7]  E. Morselli,et al.  Anti- and pro-tumor functions of autophagy. , 2009, Biochimica et biophysica acta.

[8]  Yoshiaki Kamada,et al.  Dynamics and diversity in autophagy mechanisms: lessons from yeast , 2009, Nature Reviews Molecular Cell Biology.

[9]  L. Collette,et al.  Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  C. Dowling,et al.  Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation , 2009, Molecular Cancer.

[11]  R A Knight,et al.  Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes , 2009, Cell Death and Differentiation.

[12]  J. Fitzpatrick,et al.  Hypoxia increases normal prostate epithelial cell resistance to receptor‐mediated apoptosis via AKT activation , 2009, International journal of cancer.

[13]  M. Gleave,et al.  Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy , 2008, BJU international.

[14]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  John L Cleveland,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes , 2008, Autophagy.

[16]  M. Shen,et al.  Pten inactivation and the emergence of androgen-independent prostate cancer. , 2007, Cancer research.

[17]  P. Nelson,et al.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.

[18]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[19]  B. Mellado,et al.  Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity , 2006, Clinical Cancer Research.

[20]  Allen R. Chen,et al.  The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. , 2006, Blood.

[21]  C. Morrissey,et al.  Effects of the dual 5 α‐reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines , 2006 .

[22]  D. Karunagaran,et al.  Biological and chemical inhibitors of NF‐κB sensitize SiHa cells to cisplatin‐induced apoptosis , 2005, Molecular carcinogenesis.

[23]  R. Taichman,et al.  Clusterin inhibits apoptosis by interacting with activated Bax , 2005, Nature Cell Biology.

[24]  Shadan Ali,et al.  Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. , 2005, Cancer research.

[25]  C. Morrissey,et al.  Caffeic acid phenethyl ester‐induced PC‐3 cell apoptosis is caspase‐dependent and mediated through the loss of inhibitors of apoptosis proteins , 2004, BJU international.

[26]  M. Kuo,et al.  Interleukin‐6 is responsible for drug resistance and anti‐apoptotic effects in prostatic cancer cells , 2004, The Prostate.

[27]  C. Morrissey,et al.  An antisense oligonucleotide to cIAP‐1 sensitizes prostate cancer cells to fas and TNFα mediated apoptosis , 2004, The Prostate.

[28]  M. Gleave,et al.  Silencing Expression of the Clusterin/Apolipoprotein J Gene in Human Cancer Cells Using Small Interfering RNA Induces Spontaneous Apoptosis, Reduced Growth Ability, and Cell Sensitization to Genotoxic and Oxidative Stress , 2004, Cancer Research.

[29]  C. Morrissey,et al.  Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. , 2003, Cancer.

[30]  Rakesh Nagarajan,et al.  FOXO Proteins Regulate Tumor Necrosis Factor-related Apoptosis Inducing Ligand Expression , 2002, The Journal of Biological Chemistry.

[31]  D. Hixson,et al.  Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure , 2002, Cellular and Molecular Life Sciences CMLS.

[32]  Chao-yuan Huang,et al.  Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21WAF1/CIP1 and C/EBPβ expressions and suppressing NF‐κB activation , 2002, The Prostate.

[33]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[34]  J. M. Boyd,et al.  BNIP3α A Human Homolog of Mitochondrial Proapoptotic Protein BNIP3 , 1999 .

[35]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[36]  A. Rademaker,et al.  Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  J. V. van Brussel,et al.  Multidrug Resistance in Prostate Cancer , 1997, Oncology Research and Treatment.

[38]  B. Koczwara,et al.  Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. , 1997, European journal of cancer.

[39]  C Roskelley,et al.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Vergely,et al.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. , 1993, Cancer research.

[41]  武田 匡史.  The Establishment of Two Paclitaxel-Resistant Prostate Cancer Cell Lines and the Mechanisms of Paclitaxel Resistance with Two Cell Lines , 2007 .

[42]  J. Schellens,et al.  Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. , 2006, Trends in pharmacological sciences.

[43]  J. Willis,et al.  Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer , 2006, Cell Death and Differentiation.

[44]  Michael Karin,et al.  The IKK NF-kappa B system: a treasure trove for drug development. , 2004, Nature reviews. Drug discovery.

[45]  Michael Karin,et al.  The IKK NF-κB system: a treasure trove for drug development , 2004, Nature Reviews Drug Discovery.

[46]  J. Fitzpatrick,et al.  Heat-shock proteins inhibit induction of prostate cancer cell apoptosis. , 2000, The Prostate.

[47]  J. M. Boyd,et al.  BNIP3alpha: a human homolog of mitochondrial proapoptotic protein BNIP3. , 1999, Cancer research.